Pfizer Inc., Collegeville, PA, United States of America.
Institute for Applied Health Research Berlin, Berlin, Germany.
PLoS One. 2020 Jan 28;15(1):e0228020. doi: 10.1371/journal.pone.0228020. eCollection 2020.
Limited data is available to describe clinical characteristics, long-term outcomes, healthcare resource use and the attributable costs of invasive meningococcal disease (IMD) in Germany. We aimed to examine demographic and clinical characteristics as well as healthcare resource use and related costs.
We conducted a retrospective cohort study based on the InGef database in patients with IMD between 2009 and 2015. Cases were identified based on hospital main discharge diagnoses of IMD. Demographics, clinical characteristics, 30-day and 1-year mortality as well as IMD-related complications and sequelae in IMD cases were examined. In addition, short and long-term costs and healthcare resource use in IMD cases were analyzed and compared to an age- and sex-matched control group without IMD.
The study population comprised 164 IMD cases between 2009 and 2015. The mean length of the IMD-related hospitalization was 13 days and 38% of all cases presented with meningitis only, 35% with sepsis only, 16% with both and 11% with other IMD. The 30-day and one-year mortality were 4.3% and 5.5%, respectively. Approximately 13% of IMD cases had documented IMD-related complications at hospital discharge and 24% suffered from sequelae during follow-up. The IMD-related hospitalization was associated with mean costs of € 9,620 (standard deviation: € 22,197). The difference of mean costs between IMD cases and matched non-IMD controls were € 267 in the first month and € 1,161 from one month to one year after discharged from IMD-related hospitalization. During the later follow-up period, the mean overall costs and costs associated with individual healthcare sectors were also higher for IMD cases without reaching statistical significance.
IMD resulted in severe complications and sequelae and was associated with extensive costs and increased healthcare resource use in Germany, especially in the first year after IMD diagnosis and due the IMD-related hospitalization.
关于侵袭性脑膜炎奈瑟菌病( IMD )在德国的临床特征、长期结局、医疗资源使用和可归因成本,目前仅有有限的数据可供描述。我们旨在研究人口统计学和临床特征以及医疗资源使用和相关成本。
我们基于 2009 年至 2015 年期间的 InGef 数据库进行了一项回顾性队列研究。根据 IMD 的主要住院诊断确定病例。检查 IMD 病例的人口统计学、临床特征、30 天和 1 年死亡率以及 IMD 相关并发症和后遗症。此外,还分析和比较了 IMD 病例的短期和长期成本以及医疗资源使用情况,并与无 IMD 的年龄和性别匹配对照组进行了比较。
该研究人群包括 2009 年至 2015 年期间的 164 例 IMD 病例。IMD 相关住院的平均长度为 13 天,所有病例中有 38%仅表现为脑膜炎,35%仅表现为败血症,16%同时表现为脑膜炎和败血症,11%表现为其他 IMD。30 天和 1 年死亡率分别为 4.3%和 5.5%。大约 13%的 IMD 病例在出院时记录有 IMD 相关并发症,24%在随访期间患有后遗症。IMD 相关住院与平均费用为 9620 欧元(标准差:22197 欧元)相关。在 IMD 相关住院后的第一个月,IMD 病例与匹配的非 IMD 对照组的平均费用差异为 267 欧元,从第一个月到 IMD 相关住院后一年的平均费用差异为 1161 欧元。在后续随访期间,尽管没有达到统计学意义,但 IMD 病例的总体平均费用和与个别医疗保健部门相关的费用也更高。
IMD 导致严重的并发症和后遗症,并与德国的广泛成本和增加的医疗资源使用相关,尤其是在 IMD 诊断后的第一年以及由于 IMD 相关住院。